Gastrointestinal Stromal Tumor Pipeline Drugs and Companies Insight Report, 2023 Updates: FDA Approvals, Analysis of Clinical Trials, Therapies, Route of Administration, and Developments

Gastrointestinal Stromal Tumor Overview

Gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. Itis a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs

“Gastrointestinal Stromal Tumor Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastrointestinal Stromal Tumor Market.

The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastrointestinal Stromal Tumor treatment therapies with a considerable amount of success over the years. Gastrointestinal Stromal Tumor Key players such as – IDRx, Inc., Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., and others, are developing therapies for the Gastrointestinal Stromal Tumor treatment 

• Gastrointestinal Stromal Tumor Emerging therapies such as – IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, and others are expected to have a significant impact on the Gastrointestinal Stromal Tumor market in the coming years.   
• In January 2022, Cogent Biosciences, Inc. initiated a Phase III open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients
• In August 2021, FDA Granted Orphan Drug Designation for bezuclastinib/CGT9486 in GIST (Gastrointestinal Stromal Tumors).FDA granted orphan drug designation for bezuclastinib for the treatment of GIST with an estimated 4,000 to 6,000 GIST cases diagnosed annually in the United States. Cogent remains on track to initiate a new study of bezuclastinib and sunitinib in GIST patients during 2H 2021

Route of Administration

Gastrointestinal Stromal Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment

• Gastrointestinal Stromal Tumor Assessment by Product Type
• Gastrointestinal Stromal Tumor By Stage and Product Type
• Gastrointestinal Stromal Tumor Assessment by Route of Administration
• Gastrointestinal Stromal Tumor By Stage and Route of Administration
• Gastrointestinal Stromal Tumor Assessment by Molecule Type
• Gastrointestinal Stromal Tumor by Stage and Molecule Type

DelveInsight’s Gastrointestinal Stromal Tumor Report covers around 28+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Gastrointestinal Stromal Tumor Therapeutics Market include:

Key companies developing therapies for Gastrointestinal Stromal Tumor are – Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Emerging Gastrointestinal Stromal Tumor Drugs Under Different Phases of Clinical Development Include:

• IDRX-42: IDRx, Inc.
• THE-630: Theseus Pharmaceuticals
• PDR001: Novartis
• Crenolanib: Arog Pharmaceuticals, Inc.
• Famitinib: Jiangsu HengRui Medicine Co., Ltd.
• CGT9486: Cogent Biosciences, Inc.

Get a Free Sample PDF Report to know more about Gastrointestinal Stromal Tumor Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight

Gastrointestinal Stromal Tumor Pipeline Analysis:

The Gastrointestinal Stromal Tumor pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
• Gastrointestinal Stromal Tumor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastrointestinal Stromal Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Gastrointestinal Stromal Tumor product details are provided in the report. Download the Gastrointestinal Stromal Tumor pipeline report to learn more about the emerging Gastrointestinal Stromal Tumor therapies

Gastrointestinal Stromal Tumor Pipeline Market Drivers

• Increasing prevalence of digestive disorders
• Increasing investment of biotechnology and pharmaceutical industries in research and development Availability of funds is likely to drive the growth of the Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor Pipeline Market Barriers

• Higher cost associated with the treatment procedure and hence, this is a major fact that might be responsible for slowing the market growth
• Reimbursement Policies

Scope of Gastrointestinal Stromal Tumor Pipeline Drug Insight    

• Coverage: Global
• Key Gastrointestinal Stromal Tumor Companies: IDRx, Inc., Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., and others
• Key Gastrointestinal Stromal Tumor Therapies: IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers 

Request for Sample PDF Report for Gastrointestinal Stromal Tumor Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Gastrointestinal Stromal Tumor drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis